Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary CONTROL Trial Shows Statin Therapy Reversed LDL Increases to Below Baseline Levels in NASH Patients Treated with OCA
  Low dose atorvastatin rapidly reversed OCA associated LDL changes Conference call scheduled for 8:30 am ET NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
Worldwide net Ocaliva ® (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase 2 trial in patients with PSC met its primary endpoint CONTROL trial met its objective, confirming statin co-administration with OCA reduces LDL to below baseline levels in patients with NASH Conference call
View HTML
Toggle Summary Intercept to Report Second Quarter 2017 Financial Results on July 31
NEW YORK, July 26, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its second quarter 2017
View HTML
Toggle Summary Intercept's Ocaliva® (obeticholic acid) Receives 2017 Galien Chemical Synthesis Drug Award in Italy
NEW YORK, June 22, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Ocaliva ® (obeticholic acid) has been
View HTML
Toggle Summary Intercept Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 Diabetes
Post-hoc analysis showed that patients with both type 2 diabetes and NASH had high rates of advanced fibrosis OCA-treated patients achieved statistically significant improvements in all histologic measures, including fibrosis New findings presented at the American Diabetes Association's Scientific
View HTML
Toggle Summary Health Canada Grants Approval for Ocaliva™ (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis (PBC)
Ocaliva represents the first new treatment option in over 20 years for PBC, an autoimmune liver disease that is the leading reason for liver transplantation in women in Canada 
View HTML
Toggle Summary Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid)
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has received a 2017
View HTML
Toggle Summary Intercept to Present at Upcoming Conferences
NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the
View HTML
Toggle Summary Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
Worldwide net Ocaliva ® (obeticholic acid or OCA) 1Q 2017 sales of $20.6 million Completed enrollment of Phase 3 REGENERATE trial interim analysis cohort: data expected in 1H 2019 Conference call scheduled for 8:30 a.m. ET today NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals,
View HTML
Toggle Summary Intercept to Report First Quarter 2017 Financial Results on May 4 and Present at Upcoming Conference
NEW YORK , April 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its first quarter 2017
View HTML